Gitnux/Report 2026

Medical Products Industry Statistics

309Statistics
118Sources
12Sections
1Visuals
50mRead
Medical Products Industry Statistics
Samuel NorbergWritten by Samuel Norberg·Fact-checked by Maya Johansson
Published
How this report is researched
01Editorial Scope

An editor sets the topic, the inclusion criteria, and the evaluation framework before research starts.

02Source Research

AI search agents locate sources and extract each figure together with the document it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 39 days

01 Industry overview

The medical products industry at a glance

Medical products spans pharmaceuticals and medical devices; the global prescription-drug market reached an estimated €1.41 trillion in 2024, while medtech continues to expand through digital health, robotics and specialty devices.

€1.414T[104]
Global prescription market, 2024
5.5–6.5%[105]
Pharma CAGR, 2024–2029
350,800[106]
U.S. pharma jobs, 2025
1,600+[2]
FDA-authorized AI devices, 2026
Market size
The global prescription pharmaceutical market was worth an estimated €1.414 trillion ($1.529 trillion) at ex-factory prices in 2024. In the U.S. medtech sector, Johnson & Johnson alone reported $33.8 billion in 2025 MedTech sales, illustrating the scale of the device market but not representing the whole industry.[104][23]
Forecast & CAGR
A 2025 assessment projected global pharmaceutical-market growth of approximately 5.5% to 6.5% CAGR from 2024 to 2029. EY reported that U.S. and European medtech generated $650 billion in revenue in the latest calendar year covered by its 2026 outlook, up 11%, with first-half 2026 revenue up 7% year over year.[105][24]
Market share & regions
North America accounted for 54.8% of the global prescription pharmaceutical market in 2024, compared with 22.7% for Europe, 7.1% for China and 4.0% for Japan. The figures cover retail and hospital prescription sales at ex-factory prices.[104]
Segmentation
Pharmaceutical manufacturing employment in the United States comprised about 233,200 jobs in pharmaceutical preparation manufacturing and 122,200 jobs in medicinal, botanical, in-vitro diagnostic and biological-product manufacturing in 2025. FDA medical-device activity is segmented across areas such as radiology, cardiovascular products, neurology and digital health, with AI-enabled software increasingly represented in the authorization pipeline.[106][2]
Key players & concentration
The industry is concentrated among large multinational pharmaceutical and medtech companies, although thousands of smaller biotechnology and device developers participate in research and niche markets. In 2025, new products launched within the previous five years represented approximately 25% of Johnson & Johnson sales, while its MedTech segment generated $33.8 billion.[23]
Pricing
Medicine pricing varies substantially by country because distribution margins, taxes and reimbursement rules differ. EFPIA reported that, across 25 European countries in 2023, manufacturers received an average 67.0% of the retail medicine price, while wholesalers received 10.5%, pharmacists 5.0% and the state through VAT and other taxes 17.5%.[104]
Trends, drivers & challenges
Growth is being supported by aging populations, chronic disease, specialty medicines, obesity and diabetes therapies, robotics and digital health. Key challenges include pricing pressure, foreign-exchange volatility, supply-chain resilience and the cost of clinical development; FDA data show more than 1,600 AI-enabled medical devices had been authorized for U.S. marketing by September 2026.[2][24][104]
M&A
Medtech M&A shifted toward fewer, larger transactions: EY reported $38.8 billion of M&A spending in its 2025 review, with an average deal size of $497 million, 11% higher than in 2024 and 72% above the prior decade’s average. In the first half of 2026, EY reported that average deal size increased to $2.1 billion from $0.9 billion in the first half of 2025.[24]
Regulation
Medical products are regulated through risk-based premarket and postmarket systems. For U.S. medical devices, FDA pathways include 510(k) clearance, De Novo classification and premarket approval; the agency also issued draft guidance in January 2025 addressing lifecycle management and marketing considerations for AI-enabled devices.[2]
Latest news
The latest industry developments include FDA authorization of more than 1,600 AI-enabled medical devices by September 2026 and continued medtech revenue growth in the United States and Europe. FDA’s 2025 CDRH report also recorded 44 breakthrough devices receiving marketing authorization during the year.[2][24]

02 Ranking

Top 10 Companies in the Medical Products Industry

The leading companies in the medical products industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 10, 2026 · Next review December 10, 2026

Verdict

Intuitive Surgical leads Gitnux's 2026 medical products ranking with an Overall score of 9.3, with 29.3% operating margin. Boston Scientific is the highest-ranked minimally invasive device maker at 9.2, backed by 19.9% revenue growth.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in robotic surgical systems

    Intuitive Surgical

    US

    Ranked #1 · 9.3 · Robotic surgical systems

    Why we picked it: It develops, manufactures, and markets the da Vinci robotic surgical system in robotic-assisted minimally invasive surgery.

    See in ranking ↓Visit intuitive.com ↗

  2. Leader in cardiovascular & endoscopy devices

    Boston Scientific

    US

    Ranked #2 · 9.2 · Cardiovascular & endoscopy devices

    Why we picked it: Its portfolio focuses on minimally invasive devices for cardiovascular and other specialties.

    See in ranking ↓Visit bostonscientific.com ↗

  3. Leader in imaging & diagnostics systems

    Siemens Healthineers

    DE

    Ranked #3 · 8.8 · Imaging & diagnostics systems

    Why we picked it: It operates globally in imaging, diagnostics, cancer care, and minimally invasive therapy systems.

    See in ranking ↓Visit siemens-healthineers.com ↗

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the medical products industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Intuitive Surgical

Robotic surgical systems · US

9.3
2

Boston Scientific

Cardiovascular & endoscopy devices · US

9.2
3

Siemens Healthineers

Imaging & diagnostics systems · DE

8.8
4

Medtronic

Cardiac & diabetes devices · IE

8.8
5

Johnson & Johnson

Surgical & vision franchises · US

8.8
6

Edwards Lifesciences

Structural-heart and critical-care devices · US

8.7
7

Alcon

Ophthalmic surgical and vision-care products · CH

8.2
8

GE HealthCare

Imaging, ultrasound, monitoring and diagnostics · US

8.2
9

BD

Medical essentials, diagnostics and interventional products · US

8.0
10

Danaher

Diagnostics and life-science medical products · US

7.9

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 10, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 10). Top 10 companies in the medical products industry. In Medical Products Industry Statistics. Gitnux. https://gitnux.org/medical-products-industry-statistics/#top-companies

report visual · Projection

U.S. private fixed investment in medical equipment and instruments

U.S. private fixed investment in medical equipment and instruments grew from $106.2B in 2020 to $142.2B in 2025.

$106.2B
Start
+6.01%
CAGR · 5y
$142.2B
Projected
20202025
source-verifiedapps.bea.gov2025

04 Statistics

Technology & Innovation

AI-enabled devices dominate authorization signals: more than 1,600 were authorized for U.S. marketing by September 2026. Automation uptake is mixed, with 31.4% of surveyed manufacturers reporting no automation in 2025.

AI in the medical products industry

  • 8% of surveyed pharmaceutical organizations had applied next-generation AI-enabled automation across all or most processes in 2024.[1]
  • More than 1,600 AI-enabled medical devices had been authorized for marketing in the United States by September 2026.[2]
  • 75% of surveyed pharmaceutical organizations reported using some form of advanced automation incorporating AI or machine learning in 2024.[1]
  • More than 1,300 AI-enabled medical devices had been authorized by FDA by the end of 2025.[2]
  • 1,524 AI-enabled medical devices were included on the FDA’s authorized-device list as of June 2026.[2]
  • 903 AI-enabled medical devices were listed by FDA on August 31, 2024, in a study of their clinical generalizability.[3]

Automation in the medical products industry

  • 31.4% of surveyed medical-products manufacturers reported that they were not currently using automation in 2025.[4]
  • 15.1% of pharmaceutical-sector survey respondents reported that Pharma 4.0 adoption had not started in 2023.[5]
  • 29.6% of surveyed medical-products manufacturers reported partially integrated automation in 2025.[4]
  • 53% of pharmaceutical manufacturers reported using predictive or preventive maintenance in 2025.[6]
  • 20% of pharmaceutical manufacturers reported adding AI-supported processes such as vision inspection or data analysis in 2025.[6]
  • 44% of pharmaceutical machinery buyers identified robotic controls as a desired next-generation machine improvement in 2024.[7]

Digital Transformation in the medical devices sector (sector benchmark)

  • Across medtech manufacturing executives, 64% highly prioritized digitizing manufacturing in a 2022 survey.[8]
  • Across medtech and IVD professionals worldwide, 87% said their company had implemented or planned to implement AI or digital solutions in regulatory or quality-management systems in 2020.[9]
  • Across medtech and IVD professionals worldwide, 89% said their company had implemented or planned to implement AI or digital solutions in its product range in 2020.[9]
  • Across medtech companies, 29% met or exceeded their digital-transformation targets with sustainable change in 2021, according to BCG’s global survey.[10]
  • Across medtech companies, 35% created value but failed to meet all digital-transformation targets in 2021.[10]
  • Across medtech companies, 36% achieved limited value and no sustainable change from digital transformation in 2021.[10]

Technology Adoption in the medical devices sector (sector benchmark)

  • Across healthcare industrial-ecosystem SMEs in Europe, 17.3% already used robotics in 2023.[11]
  • Across healthcare industrial-ecosystem SMEs in Europe, 31.0% already used cloud technologies in 2023.[11]
  • Across healthcare industrial-ecosystem SMEs in Europe, 13.7% already used artificial intelligence in 2023.[11]
  • Across healthcare industrial-ecosystem SMEs in Europe, 8.6% already used remote patient-monitoring technologies in 2023.[11]
  • Among emerging medtech companies, 62% had adopted electronic trial-master-file systems, compared with 89% of enterprise and global companies in the 2025 benchmark.[12]
  • Among emerging medtech companies, 38% had adopted clinical-trial-management systems, compared with 72% of enterprise and global companies in the 2025 benchmark.[12]

Cloud Computing in the medical devices sector (sector benchmark)

  • Across surveyed medtech organizations, 33% reported reliable enterprise-wide use of cloud-based technologies in 2025.[12]
  • Across medical-device manufacturing respondents in the global Industry Cloud Study, 21% reported that 75%–100% of infrastructure was in the cloud in 2022.[13]
  • Across surveyed medtech organizations, 31% managed all postmarket-surveillance processes with cloud-based technology in 2025.[12]
  • Across medical-device manufacturing respondents in the global Industry Cloud Study, 66% reported that 50%–74% of infrastructure was in the cloud in 2022.[13]

Big Data in the medical devices sector (sector benchmark)

  • Across healthcare industrial-ecosystem SMEs in Europe, 15.3% had adopted big data and related data analytics in 2023.[11]
  • 49% of medtech companies reported struggling with untimely data in Model N’s 2025 survey of industry leaders.[14]

05 Statistics

Data & Analytics

Data governance and traceability remain friction points. In a 2025 benchmark, 51% of medical-device leaders still managed postmarket-surveillance processes and data manually or partially manually.

Business intelligence in the medical products industry

  • 41% of pharmaceutical medical-affairs professionals used proprietary tools or systems to store or share insights in 2023.[15]
  • 79% of medtech leaders identified knowledge retention, including territory relationship continuity, as a critical focus in 2026.[12]
  • 68% of medtech respondents ranked the insight gap as their number-one strategic challenge in 2026.[12]
  • 99% of medtech companies surveyed considered industry benchmarking data important for revenue management.[14]
  • 84% of medtech leaders rated revenue protection through operational CRM as a high-value or critical-value priority in 2026.[12]
  • 93% of medtech companies used external sources such as channel data, industry reports, analyst data, or commissioned research for decision-making.[14]

Data analytics in the medical products industry

  • 61% of medical-device, diagnostics, and tools leaders viewed AI-driven disease diagnosis as a leading area for disruption by data analytics, AI, and machine learning in 2023.[16]
  • 68% of surveyed pharmaceutical professionals were very or quite confident that big data could transform the industry in 2024.[17]
  • 48% of medical-device corporate executives viewed disease diagnosis as highly susceptible to disruption by data analytics, AI, and machine learning in 2023.[16]
  • 59% of pharmaceutical executives planned to use artificial intelligence for revenue management in 2024.[18]
  • 48% of medical-device, diagnostics, and tools leaders viewed diagnostic imaging and image-guided therapies as a leading area for disruption by data analytics, AI, and machine learning in 2023.[16]
  • 72% of diagnostics-and-tools corporate executives viewed disease diagnosis as highly susceptible to disruption by data analytics, AI, and machine learning in 2023.[16]

Data Quality in the medical devices sector (sector benchmark)

  • 51% of medical-device companies still managed postmarket-surveillance processes and data manually or partially manually in the 2025 benchmark survey.[12]
  • 60% of medical-device professionals using literature-review software reported data traceability, compared with 4% using spreadsheets, in a global survey; survey year not stated.[19]
  • 45.9% of healthcare-sector business partners identified data quality as a major challenge in managing digital product information in the 2021 survey.[20]
  • 56% of medical-device companies used non-validated general-purpose tools for clinical data collection in the 2024 MedTech industry survey.[21]
  • 73% of medical-device professionals using literature-review software trusted their data quality, compared with 38% using spreadsheets, in a global survey; survey year not stated.[19]

Data Governance in the medical devices sector (sector benchmark)

  • 62.3% of healthcare-sector business partners identified creating a central data master as a single source of truth as the greatest digital-product-information challenge in 2021.[20]
  • 31.4% of healthcare-sector business partners had a digital-asset-management system for storing images and product data sheets in the 2021 survey.[20]
  • More than 72% of healthcare-sector business partners had not established a product-master-data system reflecting data governance in the 2021 survey.[20]
  • More than 30% of healthcare-sector business partners had no clear formal data-governance guidelines in the 2021 survey.[20]

KPIs in the medical products industry

  • 13% of lower-performing medical-device organizations were very confident they could demonstrate total product-lifecycle traceability during an unannounced audit in 2024.[21]
  • 11% of lower-performing medical-device companies reported a high level of visibility into quality problems in 2024.[21]
  • 48% of medical-device product-development professionals identified supply-chain logistics as a leading manufacturing-scaling challenge in 2024.[21]
  • 70% of medical-device organizations used outsourced clinical services either wholly or in combination with internal clinical programs in 2024.[21]
  • 35% of medical-device professionals identified the cost or effort of validating new tools or processes as a leading quality challenge in 2024.[21]
  • 23 hours per month was the reported minimum time medical-device professionals spent on reactive remediation activities in 2024.[21]

06 Statistics

Strategy & Growth

Growth and investment remain measurable across pharmaceuticals and medtech. The global MedTech industry revenue was $584 billion in 2024, up 2.1% from 2023.

Growth in the medical products industry

  • $1,188 billion was the estimated global underlying prescription-drug market in 2025, up 5.4% from 2024.[22]
  • $632 billion was the estimated underlying prescription-drug market outside the United States in 2025, up from $618 billion in 2024.[22]
  • 6.9% was the increase in Johnson & Johnson MedTech sales in the United States in 2024.[23]
  • $584 billion was the global MedTech industry's total revenue in 2024, up 2.1% from 2023.[24]
  • $1,473 billion were global pharmaceutical sales in 2024, an increase of 9.7% from 2023.[23]
  • 9.6% was Abbott's 2024 organic sales growth for its base business, reaching $42 billion in global sales.[23]

Differentiation in the medical products industry

  • 1% was the average annual revenue growth of underperforming MedTech companies in the study period.[25]
  • 16% was the average annual revenue growth of higher-performing MedTech companies in the study period.[25]
  • $1.6 billion was Boston Scientific's 2024 research-and-development investment.[23]
  • Approximately 100 products were launched by Boston Scientific in 2024.[23]
  • 150-plus new approvals, launches, line extensions and treatment indications were delivered by Abbott in 2024.[23]
  • 6.6% was 2024 revenue growth for MedTech commercial leaders.[24]

Mergers and acquisitions in the medical products industry

  • $16.5 billion was the announced value of Novo Holdings' 2024 acquisition of Catalent.[26]
  • 305 MedTech M&A transactions were announced in 2024, totaling more than $63.1 billion.[26]
  • 135 medical-technology transactions were announced in the fourth quarter of 2024.[27]
  • $497 million was the average MedTech M&A deal size in 2025, up 11% from 2024.[24]
  • $38.8 billion was total MedTech M&A spending in 2025.[24]
  • $13.1 billion was the announced value of Johnson & Johnson's 2024 acquisition of Shockwave Medical.[28]

Strategic partnerships in the medical products industry

  • 68% of the $100 billion in 2024 biopharma partnership value was categorized as licensing value in William Blair's table.[29]
  • $7.2 billion was the total announced value of MedTech licensing and R&D partnership deals in 2024 year to date.[26]
  • 8,400 million dollars were Pfizer's revenues from collaborative arrangements in 2024.[30]
  • 8% of 2024 MedTech licensing and R&D partnership deal value was paid upfront.[26]
  • 187 biopharma partnerships were announced in 2024, with approximately $11.3 billion in upfront value.[29]
  • 59% of surveyed MedTech organizations invested in strategic partnerships and joint ventures in 2024.[31]

07 Statistics

People & Workforce

Workforce planning mixes remote operations with compensation and engagement signals. Remote medical device and diagnostics employees worked 41.5 hours per week in 2023.

Hiring in the medical products industry

  • 50% of science and pharmaceutical recruiters expected recruitment budgets to decrease over the following 12 months.[32]
  • 200,536 job postings were recorded in the U.S. medical devices and equipment subsector in 2021.[33]
  • 134,553 job postings were recorded in the U.S. medical devices and equipment subsector in 2024.[33]
  • 205,155 job postings were recorded in the U.S. medical devices and equipment subsector in 2022.[33]
  • 6% of science and pharmaceutical recruiters expected recruitment budgets to increase over the following 12 months.[32]

Employee retention in the medical products industry

  • 89.0% was Ono Pharmaceutical’s three-year total retention rate in another reported year.[34]
  • 98.5% was Ono Pharmaceutical’s three-year total retention rate in another reported year.[34]
  • 93.0% was Ono Pharmaceutical’s three-year total retention rate in another reported year.[34]
  • 90.4% was Ono Pharmaceutical’s three-year total retention rate in one reported year.[34]
  • 51.2% was Sonova’s share of women in people-leader positions in another reported year.[35]

Remote Work in the medical devices sector (sector benchmark)

  • About 50% of medical device and diagnostics professionals worked fully remotely in 2023, based on 226 usable survey responses in the United States.[36]
  • Remote medical device and diagnostics employees worked an average of 41.5 hours per week in 2023, compared with 43 hours for office-based employees.[36]
  • Remote medical device and diagnostics professionals reported a median 4% pay increase in 2023, according to an industry salary survey.[36]
  • Remote medical device and diagnostics professionals reported a median salary of $142,000 in 2023, according to an industry salary survey.[36]

Hybrid Work in the medical devices sector (sector benchmark)

  • Hybrid medical device professionals reported a median salary of $150,000 in 2026, compared with $140,000 for remote and $116,000 for in-office professionals.[36]
  • Hybrid medical device and diagnostics professionals reported a median 4% pay increase in 2023, according to an industry salary survey.[36]
  • Hybrid medical device and diagnostics professionals reported a median salary of $135,000 in 2023, according to an industry salary survey.[36]
  • Hybrid medical device and diagnostics professionals represented about 40% of respondents in MD+DI’s 2023 salary survey, covering 226 usable responses.[36]

Upskilling in the medical products industry

  • 1,898 participants attended INTCO Medical’s information-and-network-security training in 2024.[37]
  • 4% of life-sciences R&D professionals reported metabolomics or transcriptomics experience in McKinsey’s analysis.[38]
  • 7% of surveyed R&D professionals moved into positions within the medical-products space.[38]
  • 40% of life-sciences R&D professionals reported biochemistry-related skills in McKinsey’s analysis.[38]
  • 41 average training hours per employee were reported by Sanofi in 2025.[39]

Employee Engagement in the medical devices sector (sector benchmark)

  • In medical devices, 23% of employees disagreed that their total compensation was fair relative to similar roles at other companies in the 2026 benchmark.[40]
  • Medical devices organizations had a median employee net promoter score of 14 in Culture Amp’s 2026 benchmark.[40]
  • In medical devices, 73% of employees were engaged in benchmark data collected from July 2025 through June 2026, predominantly across Northern America, Oceania, Europe and Asia.[40]
  • In medical devices, 91% of employees agreed they understood how their work contributed to company goals in benchmark data collected through June 2026.[40]

DEI in the medical products industry

  • 33% of pharma and medtech middle-management roles in the cited Swiss sample were held by women.[41]
  • 24.4% of executive positions across 78 large medical-device companies were held by women in 2024.[42]
  • 45% of pharma and medtech non-management roles in the cited Swiss sample were held by women.[41]

08 Statistics

Customer & Sales

Customer experience shows up in procurement sensitivity and follow-up expectations. In 2025, 42% of hospitals reported their manufacturer preference changed to some extent or a lot.

Customer experience in the medical products industry

  • 76% of medical-device users considered good customer support very important in Salesforce Research’s global consumer survey.[43]
  • 74% of global consumers were satisfied with hospital or medical-clinic experiences in 2025.[44]
  • 54% of medical-device users considered company follow-up on their progress or outcomes very important or somewhat important.[43]
  • 69% of global consumers said they would recommend a hospital or medical clinic in 2025.[44]
  • 78% of the top 50 global medtech companies substantively referenced customer experience in investor-facing communications in 2025 or 2026.[38]

Customer retention in the medical products industry

  • 65% of US healthcare professionals and procurement professionals said a negative technical-support experience could make them change medical-device suppliers.[38]
  • 42% of hospitals surveyed said their medical-device manufacturer preference had changed to some extent or a lot in 2025.[45]
  • Two in five patients used new apps to support their treatment after the COVID-19 pandemic began, according to IQVIA’s cited research.[46]
  • 3% to 8% of eligible patients used pharmaceutical patient-support programs in the cited survey evidence.[46]
  • 61% of patients found pharmaceutical patient-support programs somewhat, a little or not at all helpful in the cited survey.[46]

Customer acquisition in the medical products industry

  • 89% of healthcare professionals contacted by a medical-device representative proceeded to participate in a virtual sales call in April 2020.[47]
  • 80% of consumers owned at least one personal medical device in Propel Software’s survey of 2,000 consumers.[48]
  • 47% of consumers said they did not care who made their medical device as long as it was capable and reliable.[48]
  • 66% of healthcare professionals said the number of virtual-sales-call contacts from medical-device representatives was about right in April 2020.[47]
  • More than 1,900 medtech leaders were surveyed globally about omnichannel engagement and customer acquisition channels in McKinsey’s 2022 survey.[38]

Customer loyalty in the medical products industry

  • 55% of US consumers who tried private-label products switched back to branded options in EY’s 2025 survey; the statistic covers healthcare-related consumer-product purchasing only indirectly.[24]
  • 19.5% of pharmaceutical-product consumers said loyalty was driven equally by the merchant and the product.[49]
  • 84% of consumers who received a health alert from a personal medical device considered the data extremely or very valuable.[48]
  • 50% of US consumers said price was the most important purchasing factor in EY’s 2025 consumer survey.[24]
  • 42% of hospitals surveyed said their preference for a medical-device manufacturer had changed in 2025.[45]

Lead generation in the medical products industry

  • 33% of healthcare professionals gave medical-device virtual sales calls a rating of 4 on the survey’s seven-point effectiveness scale in April 2020.[47]
  • 57% of specialty or hospital sales representatives had access to CRM or sales-force-automation tools in the 2017 Healthcare Rep Survey.[50]
  • 5% of healthcare professionals rated medical-device virtual sales calls as very effective in April 2020.[47]
  • 89% of healthcare professionals contacted by a medical-device representative participated in a virtual sales call in April 2020.[47]
  • 11% of specialty or hospital sales representatives had access to remote-engagement tools in the 2017 Healthcare Rep Survey.[50]

09 Statistics

Marketing & Brand

Digital marketing effectiveness is tracked through measured adoption and ROI. In the U.S., 50% of medtech respondents reported digital-marketing return on investment of at least 20%.

Marketing in the medical products industry

  • 66 newly launched pharmaceutical brands spent at least $1 million on direct-to-consumer advertising and achieved at least $1 million in first-year gross sales during 2020–2024.[46]
  • $30 billion was projected U.S. healthcare and pharmaceutical media advertising expenditure in 2024, up 5% year over year.[51]
  • One in three dollars of U.S. pharmaceutical direct-to-consumer spending went to immunology in 2024.[46]
  • $6 billion was pharmaceutical-company spending on U.S. direct-to-consumer television advertising in 2024.[46]
  • 75 pharmaceutical brands each invested at least $10 million in U.S. television promotion in 2024.[46]

Digital marketing in the medical products industry

  • 45% of surveyed medtech companies considered email campaigns the most effective digital channel for generating launch opportunities.[38]
  • 40% of surveyed medtech companies considered social-media campaigns the most effective digital channel for generating launch opportunities.[38]
  • 50% of U.S. medtech respondents reported digital-marketing return on investment of at least 20%.[38]
  • 80% of surveyed medtech companies used email and social-media campaigns to launch products in 2020.[38]
  • 55% of surveyed medtech companies ran multichannel marketing campaigns across locations.[38]

Branding in the medical products industry

  • 66 was the pharmaceutical sector’s 2024 differentiation score across the seven-country index.[52]
  • 65 was the pharmaceutical sector’s 2024 inspiration score across the seven-country index.[52]
  • 65 was the pharmaceutical sector’s 2024 relevance score across the seven-country index.[52]
  • 70 was the pharmaceutical sector’s 2024 innovation score, its only high-rated reputational attribute.[52]
  • 66 was the pharmaceutical sector’s 2024 integrity score across the seven-country index.[52]

Social media in the medical products industry

  • 63% of U.S. consumers said potential risks and side effects should be disclosed in prescription-drug social-media content in 2025.[53]
  • 23% of U.S. adults recalled seeing guidance on safe medication use in prescription-drug social-media posts in 2025.[53]
  • 66% of U.S. consumers said pharmaceutical sponsorships should be disclosed in social-media content in 2025.[53]
  • 77% of U.S. prescribers were concerned about inappropriate prescribing when social-media-prompted requests were fulfilled in 2025.[53]
  • 1,004 U.S. prescribing medical professionals participated in NORC’s 2025 survey of prescription-drug social-media content.[53]

Influencer Marketing in the medical devices sector (sector benchmark)

  • 8.57 million influencer posts about the health industry were published globally in 2023, across the platforms measured by Sprout Social.[54]
  • 10% of healthcare and pharmaceutical marketers reported that they did not invest in creator or influencer marketing in 2026.[55]
  • 8% of healthcare and pharmaceutical marketers had dedicated but shrinking budgets for creator or influencer marketing in 2026.[55]
  • 29% of healthcare and pharmaceutical marketers had dedicated but flat budgets for creator or influencer marketing in 2026.[55]
  • 1.07% was the average engagement rate for health-industry influencer posts globally in 2023, across the platforms measured by Sprout Social.[54]

10 Statistics

Operations & Execution

Manufacturing execution highlights integration and quality constraints. Fully integrated automation was reported by 9.2% in 2024, while 29.6% reported partial integration.

Process optimization in the medical products industry

  • 56% of healthcare technology respondents were looking to outsource optics and sensor capabilities in 2024 globally.[56]
  • 9.2% of medical and life-sciences manufacturing respondents reported fully integrated automation in 2024, compared with 29.6% reporting partial integration globally.[4]
  • 20% of medical and life-sciences manufacturing respondents identified artificial intelligence and machine learning as the most challenging manufacturing trend in 2024 worldwide.[4]
  • 42% of healthcare technology respondents were developing additive manufacturing in-house in 2024, while 27% were looking to outsource it globally.[56]
  • 63% of U.S. medical device manufacturers planned to automate material handling in the following year, according to a 2024 capital-spending survey.[57]

Operational efficiency in the medical products industry

  • 18.9% of medical and life-sciences manufacturers identified skilled-worker shortages as the biggest obstacle to reshoring production in 2024 worldwide.[4]
  • 13% of U.S. medical device manufacturers identified in-process inventory cost as a cost-management concern in the 2024 capital-spending survey.[57]
  • 27.3% of medical and life-sciences manufacturing respondents identified reducing or managing production costs as the biggest commercialization obstacle in 2024 worldwide.[4]
  • 36% of medical and life-sciences manufacturing respondents identified workforce training and upskilling as the biggest production-line change challenge in 2024 worldwide.[4]
  • 50% of U.S. medical device manufacturers identified materials cost as a cost-management concern in the 2024 capital-spending survey.[57]

Quality management in the medical products industry

  • 137 contamination-related drug product recalls were recorded by the U.S. FDA in fiscal year 2024.[2]
  • 96 drug product recalls attributed to failed specifications were recorded by the U.S. FDA in fiscal year 2024.[2]
  • 41 defective-product drug recalls were recorded by the U.S. FDA in fiscal year 2024.[2]
  • 15.7% of reports involving devices with at least one ongoing recall were submitted late in the United States, based on 1,277,990 reports studied through 2024.[58]
  • 100 drug product recalls attributed to current good manufacturing practice deviations were recorded by the U.S. FDA in fiscal year 2024.[2]

Supply chain in the medical products industry

  • 251 new U.S. drug shortages were recorded in 2011, the peak used by FDA for comparison with later shortage counts.[2]
  • 45–90 days was the pre-pandemic lead time for azithromycin manufacturers cited by the OECD before inventories were depleted during the pandemic.[59]
  • 25% of shortage cases in one study of 20 European Economic Area countries were attributed to commercial reasons.[59]
  • 48% of European hospital pharmacists reporting medical-device shortages identified shortages or discontinuation of components, parts or accessories as a cause in 2023.[59]
  • 4% of drugs newly entering shortage during 2022–2024 were associated with product discontinuation in FDA analysis.[2]

Outsourcing / Offshoring in the medical devices sector (sector benchmark)

  • $18.5 billion was the European medtech CDMO market in 2023.[60]
  • More than half of 59 global medtech CDMO transactions in 2023 had cross-border characteristics.[60]
  • 11.4% was the year-over-year growth rate of the global medtech outsourcing market in 2023.[60]
  • 335 U.S. medical device contract manufacturers were identified in 2022, up from 314 in the prior registry.[60]
  • $81.5 billion was the global medtech outsourcing market in 2023, covering contract development and manufacturing organizations (CDMOs).[60]

11 Statistics

Finance & Pricing

Pricing pressure appears via rebates, list-price behavior, and quality-cost exposure. In the U.S., the average list-price increase associated with each additional $1 of rebates was $1.17.

Pricing strategy in the medical products industry

  • $1.17 was the average list-price increase associated with each additional $1 of pharmaceutical rebates in U.S. branded-drug data.[61]
  • 4.7% was the average annual increase in U.S. pharmaceutical net prices from 2011 to 2022.[62]
  • 9% of drugs launched in the United States during 2008–2013 had annual launch prices above $150,000.[62]
  • 3.7% was the average list-price increase across eight large drugmakers in 2025 disclosures.[63]
  • 24% was the inflation-adjusted median annual list-price increase for drugs launched in the United States from 2022 to 2024.[62]

Cost reduction in the medical products industry

  • 56% was the expected share of new medtech business awarded to strategic suppliers by fiscal 2024.[64]
  • 1.5 percentage points was the possible increase in medical-device quality costs from spikes in nonroutine compliance expenses.[38]
  • 25% was the decline in new medical-device product introductions associated with the U.S. Medicare price reductions.[65]
  • $5 billion was the estimated additional annual medical-device cost associated with nonroutine compliance-cost spikes.[38]
  • 6.8%–9.4% of medical-device industry sales represented direct quality costs in McKinsey’s industry analysis.[38]

Profitability in the medical products industry

  • 18.5% was the average net-profit margin of 228 U.S. public pharmaceutical companies in January 2026.[66]
  • 3.4% was the 2021 average net-income margin for U.S. health insurers in the prescription-drug supply chain.[67]
  • 3.5% was the 2023 average net-income margin for U.S. health insurers in the prescription-drug supply chain.[67]
  • 29.5% was the average operating-profit margin of 228 U.S. public pharmaceutical companies in January 2026.[66]
  • 3.5% was the 2017 average net-income margin for U.S. health insurers in the prescription-drug supply chain.[67]

Financial planning in the medical products industry

  • 136 billion dollars was large pharmaceutical companies’ combined R&D expenditure in 2021.[68]
  • 73% was the increase in large pharmaceutical companies’ combined R&D expenditure from 2019 to 2024.[68]
  • 75% of surveyed U.S. hospital executives said macroeconomic factors were affecting planned capital-equipment purchases.[69]
  • 163 billion dollars was large pharmaceutical companies’ combined R&D expenditure in 2023.[68]
  • 40% of surveyed U.S. hospital executives planned to cut or defer capital-equipment spending in response to macroeconomic factors.[69]

12 Statistics

Product & Service

Regulatory and postmarket activity remain central to service and lifecycle reporting. In fiscal 2024, 1,017 medical-device recalls were recorded in the United States.

Product development in the medical products industry

  • 2,508 active industry-sponsored clinical trials were recorded in Texas in 2023.[70]
  • 4,202 medical-device pre-submissions were made to the U.S. FDA in fiscal 2024.[2]
  • 78 De Novo classification requests were submitted to the U.S. FDA in fiscal 2024.[2]
  • More than $30 billion was spent directly at U.S. clinical-trial sites by biopharmaceutical companies in 2023.[70]
  • 19% was the increase in EU medical-device patent applications between 2017 and 2024.[71]

Product lifecycle in the medical products industry

  • 248 business days was the average time from completion to termination for Class III recalls initiated during U.S. fiscal years 2020–2024.[72]
  • 2,866,693 product-malfunction reports were recorded in the FDA MAUDE database from September 2019 through December 2022.[73]
  • 269 business days was the average time from completion to termination for Class II recalls initiated during U.S. fiscal years 2020–2024.[72]
  • 13,587 death reports were recorded in the FDA MAUDE database from September 2019 through December 2022.[73]
  • 1,017 medical-device recalls were recorded in the United States in fiscal 2024.[72]

After-sales in the medical products industry

  • 56% was the first-visit resolution rate among bottom-performing medical-device service teams in 2025.[74]
  • 2–3 times more repeat part replacements were recorded among bottom-performing medical-device service organizations than top performers in 2025.[74]
  • More than 9 million medical-device service events were analyzed in the 2025 service benchmark report.[74]
  • 5 times faster was the repair speed of high-performing medical-device service teams compared with the bottom 20% in 2025.[74]
  • Nearly 1 in 4 medical-device follow-up service visits were attributed to ineffective preventive maintenance in 2025.[74]

Value proposition in the medical products industry

  • $7.2 billion was the value of U.S. medical-technology exports to China in 2024.[75]
  • 488,095 jobs were supported by the U.S. medical-technology sector in 2024.[75]
  • 1.8% was the growth rate of the European medical-device market in 2025.[76]
  • 6% was the average annual growth rate of the European medical-device sector over the decade ending in 2024.[71]
  • $6.9 billion was the value of U.S. medical-technology exports to Canada in 2024.[75]

13 Statistics

Sustainability & Ethics

Sustainability reporting is increasingly comprehensive in the sector. In 2023, 88% of reported biotechnology and pharmaceutical company emissions were Scope 3 emissions.

Sustainability in the medical products industry

  • 17% of 125 pharmaceutical-manufacturing studies addressed solvent-related sustainability criteria in a 2026 global scoping review.[77]
  • 9% of 125 pharmaceutical-manufacturing studies addressed water stewardship in a 2026 global scoping review.[77]
  • 16% of 125 pharmaceutical-manufacturing studies used life-cycle assessment in a 2026 global scoping review.[77]
  • 36% of 125 pharmaceutical-manufacturing studies reported green-chemistry metrics in a 2026 global scoping review.[77]
  • 100% of Sanofi manufacturing sites were engaged in programs to monitor, manage and, where relevant, reduce industrial emissions in 2025.[78]

ESG in the medical products industry

  • 25% was the renewable-energy share of Indian pharmaceutical companies in FY2025, up from 17% in FY2023.[79]
  • 66% of pharmaceutical companies publicly disclosed ESG and sustainability performance data in the industry review.[80]
  • 88% of reported biotechnology and pharmaceutical company emissions were Scope 3 emissions in 2023.[81]
  • 53 of 66 pharmaceutical reporting organizations disclosed ESG and sustainability data through a comprehensive stand-alone report.[80]
  • 52% of biotechnology and pharmaceutical companies reported Scope 3 emissions in 2023.[81]

Ethics in the medical products industry

  • 87,000 relevant Johnson & Johnson employees completed healthcare-compliance training with an anti-corruption section in 2025.[82]
  • 95% of Johnson & Johnson sales and marketing employees completed healthcare-compliance training in 2025.[82]
  • More than 1,000 INTCO Medical employees participated in business-ethics and anti-corruption training in 2024.[37]
  • 5 business-ethics and anti-corruption training sessions were conducted by INTCO Medical in 2024.[37]
  • 348 high-risk allegations were investigated and closed by Eli Lilly in 2024.[83]

CSR in the medical products industry

  • More than 140 countries and regions were covered by the medical-products group’s certified and launched products in 2024.[84]
  • 166,000 patients were served by Amneal’s Dispensary of Hope program in 2024.[85]
  • $2.67 billion in product donations were provided by Bristol Myers Squibb in the United States in 2024.[86]
  • 121 million doses were distributed through Amneal’s Dispensary of Hope program in 2024.[85]
  • More than 3,400 invention patents had been granted by the medical-products group reporting 2024 ESG indicators.[84]

Circular economy in the medical products industry

  • 20.1% of healthcare-ecosystem respondents reported reselling or reusing products or equipment.[11]
  • 14 of 125 pharmaceutical-manufacturing studies addressed energy-use optimization in a 2026 global scoping review.[77]
  • 22.3% of healthcare-ecosystem respondents had adopted renting, leasing or related service models in the European Commission survey.[11]
  • 20.8% of healthcare-ecosystem respondents cited digital product passports or transparent supply chains as a circular practice.[11]
  • 15% of 125 pharmaceutical-manufacturing studies included recycling or circularity practices in a 2026 global scoping review.[77]

Carbon footprint in the medical products industry

  • Up to 50% carbon-dioxide savings were estimated for increased recycling and remanufacturing of medical catheters in a 2021 life-cycle study.[10]
  • 0.016 tonnes of dichloromethane were reported in Sanofi wastewater discharge in 2025.[78]
  • 15.8% was Sanofi’s reduction in total organic-carbon wastewater discharge versus its 2019 baseline in 2025.[78]
  • 25% of healthcare-sector greenhouse-gas emissions are associated with pharmaceutical production, storage, transportation and use.[80]
  • 88% of biotechnology and pharmaceutical companies’ reported emissions were Scope 3 emissions in 2023.[81]

15 Statistics

Globalization & Expansion

Trade exposure is measurable across regions and supply chains. North America accounted for 54.8% of the global prescription pharmaceutical market in 2024, compared with 22.7% for Europe.

Globalization in the medical products industry

  • The pharmaceutical industry contributed $2.295 trillion to global GDP in 2022 through direct and spillover effects.[98]
  • 96% of biologics sales in the United States are supplied through imports, according to FDA data available in 2025.[2]
  • Asia accounted for 13% of global pharmaceutical and medicine manufacturing exports by trade value in 2022.[99]
  • 49% of medical devices used in the United States are supplied through imports, according to FDA data available in 2025.[2]
  • Europe accounted for 73% of global pharmaceutical and medicine manufacturing exports by trade value in 2022.[99]

Cultural adaptation in the medical products industry

  • Culture was associated with participants’ preferences for different routes of medicine administration across 21 countries and regions in 2023.[100]
  • 60% of surveyed pharmaceutical and associated industry professionals reported disease-state education initiatives as an area where patients were involved in 2022.[101]
  • 52% of surveyed pharmaceutical and associated industry professionals reported post-launch patient education as an area where patients were involved in 2022.[101]
  • 6% of surveyed pharmaceutical and associated industry professionals defined patient centricity as including patients as authors, peer reviewers, guest editors and contributors in 2022.[101]
  • 40% of surveyed pharmaceutical and associated industry professionals identified patient representativeness as a barrier to patient and caregiver engagement in drug research and development in 2022.[101]

Supplier management in the medical products industry

  • 53% of surveyed Swiss medical-device manufacturers cited additional import and export hurdles linked to third-country status in 2023.[102]
  • 43% of surveyed Swiss medical-device suppliers cited lack of internal know-how as a major difficulty in 2023.[102]
  • 28 medical-device supply-management questions formed the basis of an industry benchmark study covering successful device manufacturers.[64]
  • 43% of surveyed Swiss medical-device suppliers cited insufficient access to reliable information as a major difficulty in 2023.[102]
  • 78% of active pharmaceutical ingredient manufacturers are located outside the United States, creating an internationally distributed supplier base in 2025.[2]

Stakeholder management in the medical products industry

  • 56% of surveyed oncology key opinion leaders interacted with clinical, medical and sales field teams in 2024.[12]
  • 13% of surveyed pharmaceutical companies measured patient impact through a survey-based question in a 2026 benchmarking study.[73]
  • 86% of surveyed oncology key opinion leaders were satisfied or very satisfied with pharmaceutical-company engagement in 2024.[12]
  • 61% of surveyed pharmaceutical companies differentiated between metrics and key performance indicators in a 2026 benchmarking study.[73]
  • 40% of surveyed pharmaceutical and associated industry professionals identified patient representativeness as a barrier to patient and caregiver engagement in 2022.[101]

Distribution channels in the medical products industry

  • The United States accounted for 8.7% of global medical-device exports in 2025.[103]
  • Medical-device imports accounted for 18.0% of global imports in the United States in 2025, making it the largest importing country.[103]
  • Germany accounted for 14.9% of global medical-device exports in 2025.[103]
  • Japan accounted for 7.1% of global medical-device exports in 2025.[103]
  • Global medical-device and equipment exports increased 2.4% in 2025 compared with 2024.[103]

Key questions about the medical products industry

What is the 2024 global prescription-drug market size in medical products?
The global prescription-drug market reached an estimated €1.41 trillion in 2024, with a 2024 global prescription market value of €1.414T at ex-factory prices.
How fast is the prescription pharmaceutical market growing from 2024 to 2029?
The forecast range for pharma CAGR from 2024 to 2029 is 5.5% to 6.5%.
Which companies lead the medical products industry?
Intuitive Surgical leads Gitnux's 2026 medical products ranking with an Overall score of 9.3, with 29.3% operating margin. Boston Scientific is the highest-ranked minimally invasive device maker at 9.2, backed by 19.9% revenue growth.
What technology shift is most visible in 2026 for medical devices?
FDA data show more than 1,600 AI-enabled medical devices authorized for U.S. marketing by September 2026.
How is the market structured among companies and contributors?
The industry is concentrated among large multinational pharmaceutical and medtech companies, while thousands of smaller biotechnology and device developers participate in research and niche markets.
Which FDA regulatory pathways and activities affect medical products in the U.S.?
For U.S. medical devices, FDA pathways include 510(k) clearance, De Novo classification, and premarket approval, with risk-based premarket and postmarket systems.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 10). Medical Products Industry Statistics. Gitnux. https://gitnux.org/medical-products-industry-statistics
MLA
Samuel Norberg. "Medical Products Industry Statistics." Gitnux, 10 Nov 2026, https://gitnux.org/medical-products-industry-statistics.
Chicago
Samuel Norberg. 2026. "Medical Products Industry Statistics." Gitnux. https://gitnux.org/medical-products-industry-statistics.

Sources & references

118 sources cited across this report

  1. arisglobal.com
  2. fda.gov
  3. jamanetwork.com
  4. go.ascentialtech.com
  5. ispe.org
  6. pmmi-fonteva.s3.us-east-1.amazonaws.com
  7. vertassets.blob.core.windows.net
  8. mastercontrol.com
  9. nsf.org
  10. bcg.com
  11. monitor-industrial-ecosystems.ec.europa.eu
  12. veeva.com
  13. pages.awscloud.com
  14. modeln.com
  15. within3.com
  16. lazard.com
  17. globaldata.com
  18. pharmamanufacturing.com
  19. distillersr.com
  20. sana-suisse-med.ch
  21. blog.greenlight.guru
  22. hardmanandco.com
  23. sec.gov
  24. ey.com
  25. rolandberger.com
  26. jpmorgan.com
  27. pmcf.com
  28. apnews.com
  29. williamblair.com
  30. investors.pfizer.com
  31. capgemini.com
  32. eploy.com
  33. ohiolifesciences.org
  34. sustainability.ono-pharma.com
  35. report.sonova.com
  36. mddionline.com
  37. intcowheelchair.com
  38. mckinsey.com
  39. scribd.com
  40. cultureamp.com
  41. advance-hsg-report.ch
  42. medicaldesignandoutsourcing.com
  43. c1.sfdcstatic.com
  44. qualtrics.com
  45. namsa.com
  46. iqvia.com
  47. ipsos.com
  48. propelsoftware.com
  49. tgcs04.toshibacommerce.com
  50. resources.indegene.com
  51. emarketer.com
  52. 5127434.fs1.hubspotusercontent-na1.net
  53. norc.org
  54. media.sproutsocial.com
  55. brand-news.it
  56. jabil.com
  57. assemblymag.com
  58. bmj.com
  59. oecd.org
  60. alirahealth.com
  61. schaeffer.usc.edu
  62. bipartisanpolicy.org
  63. drugchannels.net
  64. accelmg.com
  65. nber.org
  66. insytesbi.com
  67. csrxp.org
  68. makingpharmaindustry.it
  69. tdsecurities.com
  70. phrma.org
  71. health.ec.europa.eu
  72. files.gao.gov
  73. pmc.ncbi.nlm.nih.gov
  74. discover.aquant.ai
  75. advamed.org
  76. medtecheurope.org
  77. frontiersin.org
  78. dotcom.prod.accelerator.sanofi
  79. manufacturing.economictimes.indiatimes.com
  80. sgs.com
  81. static.seitosei-presse.com
  82. financialfilings.com
  83. sustainability.lilly.com
  84. qxb-pdf-osscache.qixin.com
  85. amneal.com
  86. esg.bms.com
  87. raps.org
  88. link.springer.com
  89. gao.gov
  90. cognition.us
  91. greenlight.guru
  92. runsafesecurity.com
  93. dennemeyer.com
  94. deloitte.com
  95. mdic.org
  96. 2bridge.partners
  97. pwc.com
  98. ifpma.org
  99. trade.gov
  100. sciencedirect.com
  101. tandfonline.com
  102. rosapeak.com
  103. krungsri.com
  104. efpia.eu
  105. sebi.gov.in
  106. bls.gov
  107. isrg.intuitive.com
  108. bostonscientific.com
  109. siemens-healthineers.com
  110. news.medtronic.com
  111. jnj.com
  112. ir.edwards.com
  113. investor.alcon.com
  114. investor.gehealthcare.com
  115. investors.bd.com
  116. investors.danaher.com
  117. who.int
  118. cms.gov